Benefits and Pitfalls of Uraemic Toxin Measurement in Peritoneal Dialysis
Open Access
- 19 February 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1395
Abstract
Chronic kidney disease is a global health burden with a rising incidence and prevalence in developed and developing nations. Once established, it results in a progressive accumulation of a myriad of uraemic toxins. Peritoneal dialysis (PD) uses the body’s peritoneal membrane to remove these toxins across a semipermeable membrane to restore and maintain homeostasis. Traditionally, dialysis adequacy has been measured through clearance of urea and creatinine. However, numerous studies have shown marginal links comparing the clearance of urea and creatinine with clinical outcomes reflected in the recent changes to the ISPD guidelines on dialysis adequacy. Instead, attention has focused on protein-bound uraemic toxins (PBTs). Produced by gut bacteria, these molecules are highly protein-bound and poorly removed by either dialysis or absorptive agents. Elevated concentrations of molecules such as p-cresyl sulfate and indoxyl sulfate have been associated with abnormal cellular function and poor patient outcomes. However, widespread use of these measures to determine dialysis adequacy has been limited by the need for specialized techniques required for measurement. Altering the gut microbiome to reduce generation of PBTs through increased dietary fiber might be an alternate approach to better patient outcomes, with some initial positive reports. This report explores advantages and limitations of measuring uraemic toxins in PD, now and in the foreseeable future.Keywords
This publication has 220 references indexed in Scilit:
- Rapid and sustainable HPLC method for the determination of uremic toxins in human plasma samplesAnalytical and Bioanalytical Chemistry, 2022
- Protein-bound uremic toxin lowering strategies in chronic kidney disease: a systematic review and meta-analysisJournal Of Nephrology, 2021
- Indoxyl sulfate‐induced calcification of vascular smooth muscle cells via the PI3K/Akt/NF‐κB signaling pathwayMicroscopy Research and Technique, 2019
- Effects of Probiotics on Inflammation and Uremic Toxins Among Patients on Dialysis: A Systematic Review and Meta-AnalysisDigestive Diseases and Sciences, 2018
- p-Cresyl sulfate promotes the formation of atherosclerotic lesions and induces plaque instability by targeting vascular smooth muscle cellsFrontiers of Medicine, 2016
- In acute kidney injury, indoxyl sulfate impairs human endothelial progenitor cells: modulation by statinAngiogenesis, 2013
- Glucose Degradation Products (GDP’s) and Peritoneal Changes in Patients on Chronic Peritoneal Dialysis: Will New Dialysis Solutions Prevent these Changes?International Urology and Nephrology, 2005
- Sulfation of indoxyl by human and rat aryl (phenol) sulfotransferases to form indoxyl sulfateEuropean Journal of Drug Metabolism and Pharmacokinetics, 2002
- Mass spectrometry in the search for uremic toxinsMass Spectrometry Reviews, 1997
- A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulinBiochemical and Biophysical Research Communications, 1985